Sacubitril/Valsartan partially alleviates myocardial infarction injury by activating the FGF21 signaling pathway via PPARs

Abstract The recent discovery of clinically significant data, alongside novel physiological and pathological occurrences surrounding sacubitril/valsartan (Sac/Val) beyond its approved indications, necessitates an urgent reevaluation of its underlying mechanism of action. In the present investigation...

Descripció completa

Dades bibliogràfiques

Autors principals:	Wenjuan Wei, Guangsen Xu, Jiaer Gao, Guiyun Wang, Ye Wang, Caiyan Li, Junwei Zheng, Huiying Lu, Yunyan Lu, Kun Wang, Hongtao Xu, Cong Wang, Xuebo Pan
Format:	Artigo
Idioma:	Inglês
Publicat:	BMC 2025-02-01
Col·lecció:	Cardiovascular Diabetology
Matèries:	Sacubitril/Valsartan Fibroblast growth factor 21 Peroxisome proliferation-activated receptor alpha Peroxisome proliferation-activated receptor gamma Myocardial infarction
Accés en línia:	https://doi.org/10.1186/s12933-025-02627-6
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!